New trends of acid-related diseases treatment

Tomoyuki Koike, Kenichiro Nakagawa, Takeshi Kanno, Katsunori Iijima, Tooru Shimosegawa

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Acid-related diseases (ARD) including gatroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) are treated by acid suppression drugs, especially proton pump inhibitor (PPI). Use of PPI as a first line therapy for ARD is recommended in various guidelines. Recently, vonoprazan, a new class of acid secretion inhibitor called potassium-competitive acid blocker (P-CAB) developed in Japan for the treatment of ARD. The drug is covered by the Japanese medical insurance for the treatment of ARD, and it is reported that Helicobacter pylori (HP) eradication rate with it is more than 90%.

Original languageEnglish
Pages (from-to)1136-1146
Number of pages11
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number7
Publication statusPublished - 2015 Jul 1


Dive into the research topics of 'New trends of acid-related diseases treatment'. Together they form a unique fingerprint.

Cite this